How many drugs in your pipeline?

Discussion in 'Avanir Pharmaceuticals' started by anonymous, May 23, 2018 at 11:12 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Anything else than what’s on your site?
     

  2. anonymous

    anonymous Guest

    3 years away from a agitation in Dementia drug
     
  3. anonymous

    anonymous Guest

    Nope. Nothing even close
     
  4. anonymous

    anonymous Guest

    Yes 3 blockbuster compounds
     
  5. anonymous

    anonymous Guest

    Yes.
     
  6. anonymous

    anonymous Guest

    lol
    3 years away at best
     
  7. anonymous

    anonymous Guest

    The problem isn't the pipeline. The compound has a ton of promise in all kinds of ways. Beyond Alz-agitation it shows promise in TBI, dementia, Parkinson's, and several other indications. Otsuka Japan knows this - it's why they bought Avanir. The question is this: Will Otsuka continue to give Wa'el and his team endless numbers of mulligans as they tank the company, just so they can someday get to the future payoff - which will likely be huge - or will Japan at some point say enough is enough? When Rohan left there was the DOJ thing and CNN was a big deal, but the fundamentals were 'ok'. Since Wa'el and his newbies have been running things, and they try to downplay this, the place is in free-fall. We lose at least a director or a manager every week or so, sales are failing as reps get enough of the iron-fisted management approach, and Wa'el marches blindly on because his ego so enormous. The day will come when Japan gets tired of pumping more money into a money-losing entity that shows no sign of righting the ship. They could just keep our R&D going, let the CMO Rick do his job, and give all of the commercial stuff to Princeton. Why not? They already have a sales force there - what's a couple more products in the bag? Then Avanir could shave off the costs of: the sales force, sales management, Sales Training, Marketing, Commercial Operations, and God knows what else. And they could shrink a bunch of other stuff like HR, Legal, IT, Finance, and that kind of stuff to just support R&D. My money is on Japan's wisdom. One way or another they will figure out a way to get value from the possibilities of the compound, it just may not be via Avanir. It's a sad situation, but that's what happens when you put amateur egomaniacs in leadership roles.
     
  8. anonymous

    anonymous Guest

    The pipeline potential isn't the issue here. The deuterated DM compound has shown very strong potential in some probably very lucrative areas. Aside from the Alz-agitation indication, it has potential benefit for TBI, Parkinson's, dimentia, and the list goes on. The issue is whether Avanir will be around to see any of that through, given the flaming nosedive it's in presently. When Rohan left there was the DOJ thing and CNN blowing up. Other than that, stuff was 'ok'. Since Wa'el and his newbies have arrived we now see revenue continuing to decline, sales reps bolting from the iron-fisted management approach that he demands from Aziz, and at HQ we lose a director or a manager every week, and the place has the vibe of a PTSD ward. Wa'el and cronies are blinded to this by their massive egos and general disdain for the workforce. Otsuka Japan has been exceedingly generous and restrained, giving Wa'el one mulligan after the next, but how long can they justify doing that (assuming that they even know about the personnel turnover and morale problems). There will come a day when they say enough is enough. They will dissolve all of Avanir that doesn't directly support the R&D organization, and tell CMO Rick to just carry on and get things done. Imagine how much less expensive it will be to run Avanir if Japan just gets rid of the commercial side of the business and gives our two products to the Princeton sales force. Whey wouldn't they - it makes total sense. What's two more products in the bag of those reps? Then they could get rid of all kinds of expenses at Avanir: the sales force, sales management, Sales Training Dept., Marketing Dept., Commercial Operations Dept., and so on. And they could shrink a bunch of other dept's that support the place: HR, Legal, IT, Finance, etc. I guess the question is whether or not Mr. Tamai reads CafePharma?
     
  9. anonymous

    anonymous Guest

    Sorry about that! I thought CP lost my first try to so I tried again and it posted both! science-minded <> blog-smart
     
  10. anonymous

    anonymous Guest

    Angry anyone?
     
  11. anonymous

    anonymous Guest

    Rick, get off CP and concentrate on getting our clinical trials back on track.
     
  12. anonymous

    anonymous Guest

    Zero Pipeline !!!!!
     
  13. anonymous

    anonymous Guest

    Pipeline in a pill. Lots to look forward too
     
  14. anonymous

    anonymous Guest

    TRUTH!
     
  15. anonymous

    anonymous Guest

    CNN anyone ?
     
  16. anonymous

    anonymous Guest

    No new drugs or indications for at least
    3 years. FDA investigation on going.
    CNN Articles crushing us.
    And now Medicare/Medicaid warning.
    And also now Insurance scrutiny that
    all but assures every script being a PA.
     
  17. anonymous

    anonymous Guest

    When is the investigation over?
     
  18. anonymous

    anonymous Guest

    lol we all have been asking the same
    question now for 3 years since they
    took our cell phones
     
  19. anonymous

    anonymous Guest

     
  20. anonymous

    anonymous Guest

    Only see 2.